Skye Bioscience, Inc. General form of registration statement for all companies including face-amount certificate companies

General form of registration statement for all companies including face-amount certificate companies

Summary of Significant Accounting Policies (Tables)

Summary of Significant Accounting Policies (Tables)

6 Months Ended

12 Months Ended

Jun. 30, 2019

Dec. 31, 2018

Accounting Policies [Abstract]

Schedule of outstanding shares of common stock equivalents were excluded from the computation of diluted earnings per share

		Three Months Ended June 30, (Unaudited)								Six Months Ended June 30, (Unaudited)
		2019				2018				2019				2018
Stock options			2,411,846				1,850,073				2,814,505				1,850,073
Unvested restricted stock			209,055				1,918,501				237,798				1,918,501
Common shares underlying convertible debt			-				-				11,722,222				-
Warrants			18,844,002				51,155,750				20,353,145				51,155,750

		Year Ended December 31,
		2018				2017
Stock options			3,600,073				1,130,000
Unvested restricted stock			1,543,501				1,050,000
Common shares underlying convertible debt			5,000,000				4,000,000
Common shares underlying convertible preferred stock			-				50,335,500
Warrants			53,130,750				11,649,500